Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   43873   clinical trials with a EudraCT protocol, of which   7293   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     

    < Back to search results

    Print Download

    Summary
    EudraCT Number:2020-004695-18
    Sponsor's Protocol Code Number:RES-Q-HR
    National Competent Authority:Germany - PEI
    Clinical Trial Type:EEA CTA
    Trial Status:Completed
    Date on which this record was first entered in the EudraCT database:2020-10-15
    Trial results
    Index
    A. PROTOCOL INFORMATION
    B. SPONSOR INFORMATION
    C. APPLICANT IDENTIFICATION
    D. IMP IDENTIFICATION
    D.8 INFORMATION ON PLACEBO
    E. GENERAL INFORMATION ON THE TRIAL
    F. POPULATION OF TRIAL SUBJECTS
    G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL
    N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED
    P. END OF TRIAL
    Expand All   Collapse All
    A. Protocol Information
    A.1Member State ConcernedGermany - PEI
    A.2EudraCT number2020-004695-18
    A.3Full title of the trial
    Reconvalescent plasma/Camostat mesylate early in Sars-CoV-2 Q-PCR positive high risk individuals
    Rekonvaleszenten Plasma / Camostat mesylat bei Sars-CoV-2 Q-PCR-positiven Personen mit hohem Risiko im Frühstadium
    A.3.1Title of the trial for lay people, in easily understood, i.e. non-technical, language
    Plasma from Covid 19 recovered patients or camostat as a therapy for early SARS-CoV-2 infection in high risk individuals
    Plasma von Covid 19-genesenen Patienten oder Camostat als Therapie für frühe SARS-CoV-2-Infektionen bei Personen mit hohem Risiko für einen schweren Verlauf
    A.3.2Name or abbreviated title of the trial where available
    RES-Q HR
    A.4.1Sponsor's protocol code numberRES-Q-HR
    A.7Trial is part of a Paediatric Investigation Plan No
    A.8EMA Decision number of Paediatric Investigation Plan
    B. Sponsor Information
    B.Sponsor: 1
    B.1.1Name of SponsorHeinrich-Heine-University Düsseldorf
    B.1.3.4CountryGermany
    B.3.1 and B.3.2Status of the sponsorNon-Commercial
    B.4 Source(s) of Monetary or Material Support for the clinical trial:
    B.4.1Name of organisation providing supportBundesministerium für Gesundheit
    B.4.2CountryGermany
    B.5 Contact point designated by the sponsor for further information on the trial
    B.5.1Name of organisationUniversity Hospital Center Düsseldorf
    B.5.2Functional name of contact pointClinic for Gastroenterology, Hepato
    B.5.3 Address:
    B.5.3.1Street AddressMoorenstr. 5
    B.5.3.2Town/ cityDüsseldorf
    B.5.3.3Post code40225
    B.5.3.4CountryGermany
    B.5.4Telephone number00492118116330
    B.5.5Fax number00492118118752
    B.5.6E-mailverena.keitel@med.uni-duesseldorf.de
    D. IMP Identification
    D.IMP: 1
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation Yes
    D.2.1.1.1Trade name Camostat mesylate
    D.2.1.2Country which granted the Marketing AuthorisationJapan
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product nameCamostat mesylate
    D.3.4Pharmaceutical form Film-coated tablet
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPOral use
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin Yes
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product No
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) No
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.8 Information on Placebo
    D.8 Placebo: 1
    D.8.1Is a Placebo used in this Trial?Yes
    D.8.3Pharmaceutical form of the placeboFilm-coated tablet
    D.8.4Route of administration of the placeboOral use
    E. General Information on the Trial
    E.1 Medical condition or disease under investigation
    E.1.1Medical condition(s) being investigated
    The novel coronavirus designated SARS CoV-2, and the disease caused by this virus designated COVID-19. No treatment is available for early disease stages and non-hospitalized patients to date. This trial focusses on SARS-CoV-2 positive patients with pre-existing risk factors for a moderate or severe COVID-19 disease course.
    E.1.1.1Medical condition in easily understood language
    SARS-CoV-2 infected patients to be treated at an early stage after positive testing and of high risk to develop moderate to severe and potentially life-threatening pneumonia.
    E.1.1.2Therapeutic area Diseases [C] - Virus Diseases [C02]
    MedDRA Classification
    E.1.2 Medical condition or disease under investigation
    E.1.2Version 23.0
    E.1.2Level LLT
    E.1.2Classification code 10053983
    E.1.2Term Corona virus infection
    E.1.2System Organ Class 100000004862
    E.1.2 Medical condition or disease under investigation
    E.1.2Version 23.0
    E.1.2Level LLT
    E.1.2Classification code 10084272
    E.1.2Term SARS-CoV-2 infection
    E.1.2System Organ Class 100000004862
    E.1.2 Medical condition or disease under investigation
    E.1.2Version 23.0
    E.1.2Level LLT
    E.1.2Classification code 10084442
    E.1.2Term SARS-CoV-2 PCR test positive
    E.1.2System Organ Class 100000004848
    E.1.2 Medical condition or disease under investigation
    E.1.2Version 23.0
    E.1.2Level LLT
    E.1.2Classification code 10084270
    E.1.2Term SARS-CoV-2 acute respiratory disease
    E.1.2System Organ Class 100000004862
    E.1.3Condition being studied is a rare disease No
    E.2 Objective of the trial
    E.2.1Main objective of the trial
    The working hypothesis to be tested in the RES-Q HR study is that the early use of camostat mesylate reduces the likelihood of disease progression to modified WHO stages 4-8 in SARS-CoV-2 positive adult patients at high risk of moderate or severe COVID-19 progression. The primary endpoint of the study is the cumulative number of individuals who progressed to or beyond category 4 on the modified WHO COVID-19 ordinal scale within 28 days after randomization.
    E.2.2Secondary objectives of the trial
    % of patients with at least 1 COVID-19-related medically visit (incl. telemedicine/phone) through day 28;
    Cumulative no. in the SoC+treatment arm vs. SoC+placebo in WHO categories 4-8 by day 8,14,56 & 90;
    Cumulative no. in the SoC+treatment arm vs. SoC+placebo in WHO categories 3 by day 8,14,28,56 & 90;
    "Event-free” survival at day 90 & evaluation of all-cause mortality at day 90 using Kaplan-Meier;
    The proportion of patients with remdesivir therapy & WHO status at initiation of remdesivir;
    The proportion of patients on dexamethasone therapy & WHO status at baseline dexamethasone;
    % of patients with novel COVID-19- associated symptoms,
    Time to resolution of COVID-19 related symptoms;
    Time to first negative SARS-CoV-2-PCR ;
    Duration of oxygen therapy (days);
    % of participants in each group with need for mechanical ventilation (& ventilation days);
    Duration of hospital stay (days), duration in intensive care (days);
    All-cause mortality at day 28
    SARS-CoV-2 genetic variants
    E.2.3Trial contains a sub-study No
    E.3Principal inclusion criteria
    1.Individuals (female, male diverse) ≥ 18 years with SARS-CoV-2 infection, confirmed by PCR before study enrollment
    2.SARS-CoV-2 positive PCR ≤ 3 days old (date of NP swab)
    3.Ability to provide written informed consent
    4.Potassium values between 3.5-4.9 mmol/l
    5.Platelets on full blood count must be ≥ 50.000/µl
    6.Presence of at least one of the following criteria:
    - Patients ≥ 55 years
    - BMI ≥ 35 kg/m2,
    - coronary artery disease (CAD),
    - chronic kidney disease (CKD) with GFR <60 ml/min but ≥ 30 ml/min,
    - diabetes mellitus,
    - active tumor disease
    -Patients with chronic pulmonary disease, e.g. obstructive pulmonary disease (COPD), pulmonary fibrosis
    E.4Principal exclusion criteria
    1.Age <18 years
    2.Unable to give informed consent
    3.Pregnant women or breast-feeding mothers
    4.Known hypersensitivity to camostat mesylate and/or severe pancreatitis
    5.Life expectancy < 6 months
    6.Duration SARS-CoV-2 typical symptoms > 3 days
    7.SARS-CoV-2 PCR detection older than 3 days
    8.SARS-CoV-2 associated clinical condition ≥ WHO stage 3 (patients hospitalized for other reasons than mAB treatment, pAB-treatment, CP-treatment,
    social reasons and COVID-19 may be included if they fulfill all inclusion and none of the exclusion criteria)
    9.Previously or currently hospitalized due to SARS-CoV-2
    10.Previous antiviral therapy for SARS-CoV-2
    11.ALT or AST > 5 x ULN at screening
    12.Liver cirrhosis > Child A (patients with Child B/C cirrhosis are excluded from the trial)
    13.Chronic kidney disease with GFR < 30 ml/min
    14.Concurrent or planned anticancer treatment during trial period
    15.Accommodation in an institution due to legal orders (§40(4) AMG).
    16.Any psycho-social condition hampering compliance with the study protocol.
    17.Evidence of current drug or alcohol abuse.
    18.Use of other investigational treatment within 5 half-lives of enrollment is prohibited
    19.Concomitant proven influenza A infection
    20.Patients with organ or bone marrow transplant in the three months prior to Screening Visit
    E.5 End points
    E.5.1Primary end point(s)
    The primary endpoint of the study is the number of individuals whose clinical status is on the COVID-19 modified WHO ordinal scale ≥ 4 up to and including day 28.
    E.5.1.1Timepoint(s) of evaluation of this end point
    Cumulative number of persons in the SoC+treatment arm versus SoC+placebo in WHO category 3 by day 28
    E.5.2Secondary end point(s)
    • Percentage of patients with at least one COVID-19-related medically attended visit through day 28. These include telemedicine/phone visits, in-person
    physician-visits, emergency department visits, and hospitalization.
    • Cumulative number of persons in the SoC+treatment arm versus SoC+placebo in WHO categories 4-8 by day 8, day 14, day 56 and day 90
    • Cumulative number of persons in the SoC+treatment arm versus SoC+placebo in WHO category 3 by day 8, day 14, day 28, day 56 and day 90
    • "Event-free” (not hospitalized, no COVID-19 associated long-term effects such secondary sclerosing cholangitis, pulmonary disease, no reinfection)
    survival at day 90 and evaluation of all-cause mortality at day 90 using Kaplan-Meier
    • The proportion of patients with remdesivir therapy and WHO status at initiation of remdesivir
    • The proportion of patients on dexamethasone therapy and WHO status at baseline dexamethasone
    • Percentage of patients with novel COVID-19-associated symptoms after enrolment
    • Time to resolution of COVID-19-related symptoms (e.g. fever)
    • Time to first negative SARS-CoV-2-PCR
    • Duration of oxygen therapy (in days)
    • Frequency of occurrence of COVID-19 pneumonia
    • Percentage of participants in each group with need for mechanical ventilation (and ventilation days)
    • Duration of hospital stay (in days), duration in intensive care/IMC (in days)
    • All-cause mortality at day 28
    • Cumulative incidence of SAEs per group within 90 days follow up
    • Cumulative incidence of grade 3/4 AEs per group
    • SARS-CoV-2 antibody concentrations (IgA, IgG, NT) in serum on baseline, day 8, day 14, day 90
    • SARS-CoV-2 genetic variants (at baseline) and accumulation of variants of concern (VOC) during treatment period (at last positive PCR test)
    • Change of Quality of life from baseline to day 28, day 90 (VAS, SF-12)
    E.5.2.1Timepoint(s) of evaluation of this end point
    Results of study visits day 8, day 14, day 28, day 56 and day 90 after inclusion into the study.
    E.6 and E.7 Scope of the trial
    E.6Scope of the trial
    E.6.1Diagnosis No
    E.6.2Prophylaxis No
    E.6.3Therapy Yes
    E.6.4Safety Yes
    E.6.5Efficacy Yes
    E.6.6Pharmacokinetic No
    E.6.7Pharmacodynamic No
    E.6.8Bioequivalence No
    E.6.9Dose response No
    E.6.10Pharmacogenetic No
    E.6.11Pharmacogenomic No
    E.6.12Pharmacoeconomic No
    E.6.13Others No
    E.7Trial type and phase
    E.7.1Human pharmacology (Phase I) No
    E.7.1.1First administration to humans No
    E.7.1.2Bioequivalence study No
    E.7.1.3Other No
    E.7.1.3.1Other trial type description
    E.7.2Therapeutic exploratory (Phase II) Yes
    E.7.3Therapeutic confirmatory (Phase III) No
    E.7.4Therapeutic use (Phase IV) No
    E.8 Design of the trial
    E.8.1Controlled Yes
    E.8.1.1Randomised Yes
    E.8.1.2Open No
    E.8.1.3Single blind No
    E.8.1.4Double blind No
    E.8.1.5Parallel group No
    E.8.1.6Cross over No
    E.8.1.7Other Yes
    E.8.1.7.1Other trial design description
    2-arm, multicenter, randomized, double-blind, controlled trial
    E.8.2 Comparator of controlled trial
    E.8.2.1Other medicinal product(s) No
    E.8.2.2Placebo Yes
    E.8.2.3Other No
    E.8.2.4Number of treatment arms in the trial2
    E.8.3 The trial involves single site in the Member State concerned No
    E.8.4 The trial involves multiple sites in the Member State concerned Yes
    E.8.4.1Number of sites anticipated in Member State concerned10
    E.8.5The trial involves multiple Member States No
    E.8.6 Trial involving sites outside the EEA
    E.8.6.1Trial being conducted both within and outside the EEA No
    E.8.6.2Trial being conducted completely outside of the EEA No
    E.8.7Trial has a data monitoring committee Yes
    E.8.8 Definition of the end of the trial and justification where it is not the last visit of the last subject undergoing the trial
    LVLS
    E.8.9 Initial estimate of the duration of the trial
    E.8.9.1In the Member State concerned years1
    E.8.9.1In the Member State concerned months6
    E.8.9.1In the Member State concerned days
    F. Population of Trial Subjects
    F.1 Age Range
    F.1.1Trial has subjects under 18 No
    F.1.1.1In Utero No
    F.1.1.2Preterm newborn infants (up to gestational age < 37 weeks) No
    F.1.1.3Newborns (0-27 days) No
    F.1.1.4Infants and toddlers (28 days-23 months) No
    F.1.1.5Children (2-11years) No
    F.1.1.6Adolescents (12-17 years) No
    F.1.2Adults (18-64 years) Yes
    F.1.2.1Number of subjects for this age range: 398
    F.1.3Elderly (>=65 years) Yes
    F.1.3.1Number of subjects for this age range: 95
    F.2 Gender
    F.2.1Female Yes
    F.2.2Male Yes
    F.3 Group of trial subjects
    F.3.1Healthy volunteers No
    F.3.2Patients Yes
    F.3.3Specific vulnerable populations Yes
    F.3.3.1Women of childbearing potential not using contraception No
    F.3.3.2Women of child-bearing potential using contraception Yes
    F.3.3.3Pregnant women No
    F.3.3.4Nursing women No
    F.3.3.5Emergency situation No
    F.3.3.6Subjects incapable of giving consent personally No
    F.3.3.7Others No
    F.4 Planned number of subjects to be included
    F.4.1In the member state497
    F.5 Plans for treatment or care after the subject has ended the participation in the trial (if it is different from the expected normal treatment of that condition)
    None
    G. Investigator Networks to be involved in the Trial
    N. Review by the Competent Authority or Ethics Committee in the country concerned
    N.Competent Authority Decision Authorised
    N.Date of Competent Authority Decision2020-12-02
    N.Ethics Committee Opinion of the trial applicationFavourable
    N.Ethics Committee Opinion: Reason(s) for unfavourable opinion
    N.Date of Ethics Committee Opinion2020-11-12
    P. End of Trial
    P.End of Trial StatusCompleted
    P.Date of the global end of the trial2021-10-29
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Wed May 08 04:58:20 CEST 2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA